COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ)
$35.47 0.22 (0.6241%)
Analysed COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) News Sources
How The Collegium Pharmaceutical (COLL) Narrative Is Evolving On A Modest Target Price Shift
12-04-2026
yahoo.com
3 Cash-Producing Stocks Walking a Fine Line
10-04-2026
yahoo.com
Collegium to Participate in Upcoming Investor Conferences
08-04-2026
yahoo.com
1 Value Stock on Our Buy List and 2 Facing Headwinds
06-04-2026
yahoo.com
GE HealthCare and Collegium Pharmaceutical Stocks Trade Down, What You Need To Know
03-04-2026
yahoo.com
2 Profitable Stocks to Consider Right Now and 1 We Question
02-04-2026
yahoo.com
Is Collegium Pharmaceutical (COLL) One of the Best Small-Cap Drug Manufacturers
31-03-2026
yahoo.com
Collegium's General Counsel Trims His Stake as the Company Doubles Down on ADHD
31-03-2026
fool.com
Collegium’s AZSTARYS Deal And Insider Sale Put Focus On Valuation
27-03-2026
yahoo.com
Branded Pharmaceuticals Stocks Q4 Recap: Benchmarking Collegium Pharmaceutical (NASDAQ:COLL)
26-03-2026
yahoo.com
What is the current price of COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ)?
The current price of COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) is $35.47.
COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) absolute price change since previous trading day?
The absolute price change of COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) since the previous trading day is $0.22.
COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) percentage price change since previous trading day?
The percentage price change of COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) since the previous trading day is 0.6241%.
What is the most recent average sentiment score for COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ)?
The most recent average sentiment score for COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) is 77 out of 100.
What is the most recent average sentiment for COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ)?
The most recent sentiment for COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ) is .
SEC-8K** Filing Available For COLLEGIUM PHARMACEUTICAL INC (COLL:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.